Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D005355 | Fibrosis NIH | 0.29 |
D017563 | Lung Diseases, Interstitial NIH | 0.27 |
D011658 | Pulmonary Fibrosis NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006515 | Interstitial pneumonitis HPO | 0.27 |
HP:0002206 | Pulmonary fibrosis HPO | 0.26 |
HP:0002088 | Abnormal lung morphology HPO | 0.22 |
Navigate: Correlations HPO
There is one clinical trial.
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
Description: The severity of pulmonary tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group according to the results of a blinded central laboratory
Measure: The severity of lung tissue lesions with fibrosis and interstitial changes on day 75 Time: Day 0, Day 75Description: The severity of lung tissue damage by fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 6 months in relation to the baseline values of the indicator in patients of the Longidaze® group in comparison with the the dynamic observation group (according to the results of a blinded central laboratory)
Measure: The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180 Time: Day 0, Day 180Description: The severity of lung tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group (according to the results of the local laboratory)
Measure: The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180 Time: Day 0, Day 75, Day 180Description: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) based on the high-resolution computed tomography images analyzed by the Botkin.AI program (artificial intelligence) and then verified by a specialist after 2.5 months and 6 months from the beginning of observation in relation to the baseline values of indicators in patients of the Longidaze® group in comparison with the dynamic observation group
Measure: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence) Time: Day 75, Day 180Description: Change in forced vital capacity FVC (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group
Measure: Change in forced vital capacity (FVC) Time: Day 0, Day 75, Day 180Description: Change in the diffusion capacity of the lungs (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group
Measure: Change in the diffusion capacity of the lungs Time: Day 0, Day 75, Day 180Description: Change in the degree of dyspnea on the MMRC scale from baseline after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. MMRC scale (Modified Medical Research Council scale) 0 - no - Dyspnea does not bother, except for very intense exercise - mild - Shortness of breath bothers with brisk walking or climbing a small elevation - moderate to severe - Shortness of breath results in slower walking compared to other people of the same age, or need to stop while walking at normal pace on a level surface - Severe - Shortness of breath makes you stop when walking about 100 m or after a few minutes of walking on a flat surface - very severe - Shortness of breath makes it impossible to leave the house or appears when dressing and undressing
Measure: Change in the degree of dyspnea on the MMRC scale Time: Day 0, Day 75, Day 180Description: Changes in SpO2 of capillary blood relative to the initial value after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.
Measure: Changes in capillary blood oxygen saturation (SpO2) Time: Day 0, Day 75, Day 180Description: Changes in the covered footage in the 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.
Measure: Changes in the covered footage in the 6-minute walk test Time: Day 0, Day 75, Day 180Description: Changes in capillary blood saturation (SpO2) after a 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.
Measure: Changes in capillary blood saturation (SpO2) after a 6-minute walk test Time: Day 0, Day 75, Day 180Description: Change in the residual volume of the lungs after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.
Measure: Change in the residual volume of the lungs Time: Day 0, Day 75Description: Change in the total lung capacity after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.
Measure: Change in the total lung capacity Time: Day 0, Day 75Description: Change in inspiratory capacity after 2.5 months in patients of the Longidaze® group compared with dynamic observation group
Measure: Change in inspiratory capacity Time: Day 75Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports